Source comparison
CJC-1295 No DAC vs DAC-Modified: Adverse Event Comparison
Plasma Half-Life ~30 minutes 6–8 days No DAC version clears rapidly, limiting systemic exposure window Common Adverse Events Injection-site reactions (18%), transient flushing (6–15%), mild headache (9%) Injection-site nodules (35–40%), sustained flushing (20–
This comparison does not assign a generated winner or score.
- Plasma Half-Life
- ~30 minutes
- 6–8 days
- No DAC version clears rapidly, limiting systemic exposure window
- Common Adverse Events
- Injection-site reactions (18%), transient flushing (6–15%), mild headache (9%)
- Injection-site nodules (35–40%), sustained flushing (20–30%), fluid retention (15–25%), joint stiffness (10–18%)
- DAC modification increases both frequency and severity of side effects
- Serious Adverse Events (Grade 3+)
- 0% across published trials
- Rare but documented: one case of acute pancreatitis (2015 case report), isolated reports of cardiac arrhythmia
- No DAC version has substantially better safety margin
- Dosing Frequency
- Twice weekly to daily
- Once weekly to every 2 weeks
- More frequent dosing with No DAC allows tighter control and dose adjustment
- Immune Reaction Pattern
- Decreasing incidence with repeated dosing (tolerance)
- Stable or increasing incidence (sensitization possible)
- DAC acts as hapten, potentially driving antibody formation
- Bottom Line
- First-line choice for protocols requiring GH pulse stimulation with minimal systemic exposure
- Reserve for applications specifically requiring sustained GH elevation despite higher adverse event burden
- No DAC version appropriate for broader range of research contexts